泰它西普将引领2024 年收入实现高增长，股东净亏损缩小公司公布2024 年盈利预告，预计2024 年销售收入将同比增加近六成至约17.15 亿元（人民币，下同），股东净亏损将较去年同期缩小约4,100 万元至约14.7 亿元。公司主要产品泰它西普在红斑狼疮等适应症上销售收入大幅增加，导致收入超预期。公司四季度加大销售推广投入，导致股东净亏损多于预期，但是仍将成功实现同比减亏。主要产品的新适应症与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.